Pharmacological options for narcolepsy: are they the way forward?

References

• Black J, Reaven NL, Funk SE, et al. Medical comorbidity in narcolepsy: findings from the burden of narcolepsy disease (BOND) study. Sleep Med. 2017 May; 33:13–18. Epub 2016 May 12. PMID: 28449892. doi: 10.1016/j.sleep.2016.04.004.
   PubMed Web of Science ®Google Scholar
• Ruoff CM, Reaven NL, Funk SE, et al. High rates of psychiatric comorbidity in narcolepsy: findings from the burden of narcolepsy disease (BOND) study of 9,312 patients in the United States. J Clin Psychiatry. 2017 Feb;78(2):171–176. PMID: 27835717. doi: 10.4088/JCP.15m10262.
   PubMed Web of Science ®Google Scholar
• Ohayon MM, Black J, Lai C, et al. Increased mortality in narcolepsy. Sleep. 2014 Mar 1;37(3):439–444. PMID: 24587565; PMCID: PMC3920308. doi: 10.5665/sleep.3470
   PubMed Web of Science ®Google Scholar
• Black J, Reaven NL, Funk SE, et al. The burden of narcolepsy disease (BOND) study: health-care utilization and cost findings. Sleep Med. 2014 May;15(5):522–529. Epub 2014 Feb 15. PMID: 24768358. doi: 10.1016/j.sleep.2014.02.001
   PubMed Web of Science ®Google Scholar
• Thorpy MJ, Hiller G. The medical and economic burden of narcolepsy: implications for managed care. Am Health Drug Benefits. 2017 Jul;10(5):233–241. PMID: 28975007; PMCID: PMC5620503.
   PubMed Web of Science ®Google Scholar
• American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014. p. 143–160.
   Google Scholar
• Guilleminault C, VC A. Narcolepsy Chokroverty S, editor. Philadelphia: Saunders; 2009. p. 377–396. 10.1016/B978-0-7506-7584-0.00027-6
   Google Scholar
• Bassetti CLA, Adamantidis A, Burdakov D, et al. Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019 Sep;15(9):519–539. Epub 2019 Jul 19. PMID: 31324898. doi: 10.1038/s41582-019-0226-9
   PubMed Web of Science ®Google Scholar
• Barateau L, Pizza F, Plazzi G, et al. Narcolepsy. J Sleep Res. 2022 Aug;31(4):e13631. Epub 2022 May 27. PMID: 35624073. doi: 10.1111/jsr.13631
   PubMedGoogle Scholar
• Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep. 2017 Mar 3;9: 39–57. PMID: 28424564; PMCID: PMC5344488. doi: 10.2147/NSS.S103467
   PubMed Web of Science ®Google Scholar
• Scammell TE Clinical features and diagnosis of narcolepsy. In UptoDate. [cited 2023 Mar 9]. Available from: https://www-uptodate-com.laneproxy.stanford.edu/contents/clinical-features-and-diagnosis-of-narcolepsy-inadults?search=clinical%20features%20and%20diagnosis%20of%20narcolepsy%20in%20adults&source=search_result&selectedTitle=1~120&usage_type=default&display_rank=1
   Google Scholar
• Mignot E, Zeitzer J, Pizza F, et al. Sleep problems in narcolepsy and the role of hypocretin/orexin deficiency. Front Neurol Neurosci. 2021;45:103–116. Epub 2021 May 28. PMID: 34052809. doi: 10.1159/000514959.
   PubMedGoogle Scholar
• Dauvilliers Y, Siegel JM, Lopez R, et al. Cataplexy–clinical aspects, pathophysiology, and management strategy. Nat Rev Neurol. 2014 Jul;10(7):386–395. Epub 2014 Jun 3. PMID: 24890646; PMCID: PMC8788644. doi: 10.1038/nrneurol.2014.97
   PubMed Web of Science ®Google Scholar
• Poryazova R, Khatami R, Werth E, et al. Weak with sex: sexual intercourse as a trigger for cataplexy. J Sex Med. 2009 Aug;6(8):2271–2277. Epub 2009 Jun 2. PMID: 19493288. doi: 10.1111/j.1743-6109.2009.01328.x
   PubMed Web of Science ®Google Scholar
• Pizza F, Antelmi E, Vandi S, et al. The distinguishing motor features of cataplexy: a study from video-recorded attacks. Sleep. 2018 May 1;41(5). PMID: 29425380. doi: 10.1093/sleep/zsy026
   Web of Science ®Google Scholar
• Leu-Semenescu S, De Cock VC, Le Masson VD, et al. Hallucinations in narcolepsy with and without cataplexy: contrasts with parkinson’s disease. Sleep Med. 2011 May;12(5):497–504. Epub 2011 Apr 12. PMID: 21486708. doi: 10.1016/j.sleep.2011.03.006
   PubMed Web of Science ®Google Scholar
• Vignatelli L, Antelmi E, Ceretelli I, et al. Red flags for early referral of people with symptoms suggestive of narcolepsy: a report from a national multidisciplinary panel. Neurol Sci. 2019 Mar;40(3):447–456. Epub 2018 Dec 12. PMID: 30539345; PMCID: PMC6433801. doi: 10.1007/s10072-018-3666-x
   PubMed Web of Science ®Google Scholar
• Nightingale S, Orgill JC, Ebrahim IO, et al. The association between narcolepsy and REM behavior disorder (RBD). Sleep Med. 2005 May;6(3):253–258. PMID: 15854856. doi: 10.1016/j.sleep.2004.11.007
   PubMed Web of Science ®Google Scholar
• Nevsimalova S, Prihodova I, Kemlink D, et al. REM behavior disorder (RBD) can be one of the first symptoms of childhood narcolepsy. Sleep Med. 2007 Nov;8(7–8):784–786. Epub 2007 Jun 13. PMID: 17569582. doi: 10.1016/j.sleep.2006.11.018
   PubMed Web of Science ®Google Scholar
• Roth T, Dauvilliers Y, Mignot E, et al. Disrupted nighttime sleep in narcolepsy. J Clin Sleep Med. 2013 Sep 15;9(9): 955–965. PMID: 23997709; PMCID: PMC3746724. 10.5664/jcsm.3004.
   PubMed Web of Science ®Google Scholar
• Maski K, Steinhart E, Williams D, et al. Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy. J Clin Sleep Med. 2017 Mar 15;13(3): 419–425. PMID: 27923434; PMCID: PMC5337589. 10.5664/jcsm.6494.
   PubMed Web of Science ®Google Scholar
• Kotagal S, Nichols CD, Grigg‐Damberger MM, et al. Non‐ respiratory indications for polysomnography and related procedures in children: an evidence‐based review. Sleep. 2012;35(11):1451‐1466. doi: 10.5665/sleep.2188
   Web of Science ®Google Scholar
• Pizza F, Barateau L, Jaussent I, et al. Validation of multiple sleep latency test for the diagnosis of pediatric narcolepsy type 1. Neurology. 2019 Sep 10;93(11):e1034–e1044. Epub 2019 Aug 12. PMID: 31405906. doi: 10.1212/WNL.0000000000008094
   PubMed Web of Science ®Google Scholar
• Mansukhani MP, Dhankikar S, Kotagal S, et al. The influence of antidepressants and actigraphy-derived sleep characteristics on pediatric multiple sleep latency testing. J Clin Sleep Med. 2021 Nov 1;17(11): 2179–2185. PMID: 34013880; PMCID: PMC8636371. 10.5664/jcsm.9338.
   PubMed Web of Science ®Google Scholar
• Lammers GJ, Bassetti CLA, Dolenc-Groselj L, et al. Diagnosis of central disorders of hypersomnolence: a reappraisal by European experts. Sleep Med Rev. 2020 Aug;52:101306. Epub 2020 Mar 23. PMID: 32311642. doi: 10.1016/j.smrv.2020.101306
   PubMed Web of Science ®Google Scholar
• Maski K, Mignot E, Scammell TE, et al. Diagnosis of central disorders of hypersomnolence: challenges in defining central disorders of hypersomnolence. Sleep Med Rev. 2020 Aug;52:101327. Epub 2020 May 6. PMID: 32554241. doi: 10.1016/j.smrv.2020.101327
   PubMed Web of Science ®Google Scholar
• Fronczek R, Arnulf I, Baumann CR, et al. To split or to lump? Classifying the central disorders of hypersomnolence. Sleep. 2020 Aug 12;43(8):zsaa044. PMID: 32193539; PMCID: PMC7420691. doi: 10.1093/sleep/zsaa044
   PubMed Web of Science ®Google Scholar
• Gool JK, Zhang Z, Oei MSSL, et al. Data-driven phenotyping of central disorders of hypersomnolence with unsupervised clustering. Neurology. 2022 Jun 7;98(23):e2387–e2400. Epub 2022 Apr 18. Erratum in: Neurology. 2023 Jan 24;: PMID: 35437263; PMCID: PMC9202524. doi: 10.1212/WNL.0000000000200519
   PubMed Web of Science ®Google Scholar
• Zhang Z, Dauvilliers Y, Plazzi G, et al. Idling for decades: a European study on risk factors associated with the delay before a narcolepsy diagnosis. Nat Sci Sleep. 2022 May 31;14:1031–1047. PMID: 35669411; PMCID: PMC9166906. doi: 10.2147/NSS.S359980
   PubMed Web of Science ®Google Scholar
• Thorpy MJ, Krieger AC. Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med. 2014 May;15(5):502–507. Epub 2014 Feb 15. PMID: 24780133. doi: 10.1016/j.sleep.2014.01.015
   PubMed Web of Science ®Google Scholar
• Rosenberg R, Kim AY. The AWAKEN survey: knowledge of narcolepsy among physicians and the general population. Postgrad Med. 2014 Jan;126(1):78–86. PMID: 24393754. doi: 10.3810/pgm.2014.01.2727
   PubMed Web of Science ®Google Scholar
• Quaedackers L, Pillen S, Overeem S. Recognizing the symptom spectrum of narcolepsy to improve timely diagnosis: a narrative review. Nat Sci Sleep. 2021 Jul 7;13: 1083–1096. PMID: 34262379; PMCID: PMC8273742. doi: 10.2147/NSS.S278046
   PubMed Web of Science ®Google Scholar
• Thorpy M, Morse AM. Reducing the clinical and socioeconomic burden of narcolepsy by earlier diagnosis and effective treatment. Sleep Med Clin. 2017 Mar;12(1):61–71. PMID: 28159098. doi: 10.1016/j.jsmc.2016.10.001
   PubMedGoogle Scholar
• Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002 Oct;59(10):1553–1562. PMID: 12374492. doi: 10.1001/archneur.59.10.1553
   PubMed Web of Science ®Google Scholar
• Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000 Jan 1;355(9197): 39–40. PMID: 10615891. 10.1016/S0140-6736(99)05582-8.
   PubMed Web of Science ®Google Scholar
• Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000 Sep;27(3):469–474. PMID: 11055430; PMCID: PMC8760623. doi: 10.1016/s0896-6273(00)00058-1
   PubMed Web of Science ®Google Scholar
• Bourgin P, Zeitzer JM, Mignot E. CSF hypocretin-1 assessment in sleep and neurological disorders. Lancet Neurol. 2008 Jul;7(7):649–662. Erratum in: Lancet Neurol. 2008 Sep;7(9):771. PMID: 18565458. doi: 10.1016/S1474-4422(08)70140-6
   PubMed Web of Science ®Google Scholar
• Naganuma F, Bandaru SS, Absi G, et al. Melanin-concentrating hormone neurons contribute to dysregulation of rapid eye movement sleep in narcolepsy. Neurobiol Dis. 2018 Dec;120:12–20. Epub 2018 Aug 24. PMID: 30149182; PMCID: PMC6195361. doi: 10.1016/j.nbd.2018.08.012
   PubMed Web of Science ®Google Scholar
• Bassetti CLA, Kallweit U, Vignatelli L, et al. European guideline and expert statements on the management of narcolepsy in adults and children. J Sleep Res. 2021 Dec;30(6):e13387. Epub 2021 Jun 25. PMID: 34173288. doi:10.1111/jsr.13387. .
   PubMed Web of Science ®Google Scholar
• Buonocore SM, van der Most RG. Narcolepsy and H1N1 influenza immunology a decade later: what have we learned? Front Immunol. 2022 Oct 12;13: 902840. PMID: 36311717; PMCID: PMC9601309. doi: 10.3389/fimmu.2022.902840
   PubMed Web of Science ®Google Scholar
• Mahlios J, De la Herrán-Arita AK, Mignot E. The autoimmune basis of narcolepsy. Current Opinion In Neurobiology. 2013 Oct;23(5):767–773. Epub 2013 May 29. PMID: 23725858; PMCID: PMC3848424. doi: 10.1016/j.conb.2013.04.013
   PubMed Web of Science ®Google Scholar
• Aran A, Lin L, Nevsimalova S, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep. 2009 Aug;32(8):979–983. PMID: 19725248; PMCID: PMC2717204. doi: 10.1093/sleep/32.8.979
   PubMed Web of Science ®Google Scholar
• Ollila HM, Sharon E, Lin L, et al. Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy. Nat Commun. 2023 May 15;14(1):2709. PMID: 37188663; PMCID: PMC10185546. doi: 10.1038/s41467-023-36120-z
   PubMed Web of Science ®Google Scholar
• Latorre D, Kallweit U, Armentani E, et al. T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature. 2018 Oct;562(7725):63–68. Epub 2018 Sep 19. PMID: 30232458. doi: 10.1038/s41586-018-0540-1
   PubMed Web of Science ®Google Scholar
• Lecendreux M, Churlaud G, Pitoiset F, et al. Narcolepsy type 1 is associated with a systemic increase and activation of regulatory T cells and with a systemic activation of Global T cells. PLoS One. 2017 Jan 20;12(1): e0169836. PMID: 28107375; PMCID: PMC5249232. 10.1371/journal.pone.0169836.
   PubMed Web of Science ®Google Scholar
• Kornum BR, Burgdorf KS, Holm A, et al. Absence of autoreactive CD4+ T-cells targeting HLA-DQA1*01: 02/DQB1*06: 02 restricted hypocretin/orexin epitopes in narcolepsy type 1 when detected by EliSpot. J Neuroimmunol. 2017 Aug 15;309:7–11. Epub 2017 May 4. PMID: 28601291. doi: 10.1016/j.jneuroim.2017.05.001
   PubMed Web of Science ®Google Scholar
• Kornum BRNarcolepsy type 1 as an autoimmune disorder, in handbook of clinical NeurologyEdited bySwaab DF, Buijs RM, Lucassen PJ, Salehi A, and Kreier F. 2021;Vol. 181:p. 161–172.s. Elsevier BV. doi: 10.1016/B978-0-12-820683-6.00012-9
   Google Scholar
• Pedersen NW, Holm A, Kristensen NP, et al. CD8+ T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens. Nat Commun. 2019 Feb 19;10(1):837. PMID: 30783092; PMCID: PMC6381094. doi: 10.1038/s41467-019-08774-1
   PubMedGoogle Scholar
• Luo G, Ambati A, Lin L, et al. Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy. Proc Natl Acad Sci U S A. 2018 Dec 26;115(52): E12323–E12332. Epub 2018 Dec 12. PMID: 30541895; PMCID: PMC6310865. 10.1073/pnas.1818150116.
   PubMed Web of Science ®Google Scholar
• Kawashima M, Lin L, Tanaka S, et al. Anti-tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep. 2010 Jul;33(7):869–874. PMID: 20614846; PMCID: PMC2894428. doi: 10.1093/sleep/33.7.869
   PubMed Web of Science ®Google Scholar
• Andlauer O, Moore H 4th, Hong SC, et al. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep. 2012 Sep 1;35(9): 1247–55F. PMID: 22942503; PMCID: PMC3413802. 10.5665/sleep.2080.
   PubMed Web of Science ®Google Scholar
• Baumann-Vogel H, Schreckenbauer L, Valko PO, et al. Narcolepsy type 2: a rare, yet existing entity. J Sleep Res. 2021 Jun;30(3):e13203. Epub 2020 Sep 29. PMID: 32989797. doi: 10.1111/jsr.13203
   PubMed Web of Science ®Google Scholar
• Thannickal TC, Nienhuis R, Siegel JM. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep. 2009 Aug;32(8):993–998. PMID: 19725250; PMCID: PMC2717206. doi: 10.1093/sleep/32.8.993
   PubMed Web of Science ®Google Scholar
• Baumann CR, Mignot E, Lammers GJ, et al. Challenges in diagnosing narcolepsy without cataplexy: a consensus statement. Sleep. 2014;37(6):1035–1042. doi: 10.5665/sleep.3756
   PubMed Web of Science ®Google Scholar
• Longstreth WT Jr, Koepsell TD, Ton TG, et al. The epidemiology of narcolepsy. Sleep. 2007 Jan;30(1):13–26. PMID: 17310860. doi: 10.1093/sleep/30.1.13
   PubMed Web of Science ®Google Scholar
• Khatami R, Luca G, Baumann CR, et al. European narcolepsy network. The European narcolepsy network (EU-NN) database. J Sleep Res. 2016 Jun;25(3):356–364. Epub 2016 Jan 26. PMID: 26809504. doi: 10.1111/jsr.12374
   PubMed Web of Science ®Google Scholar
• Gudka S, Haynes E, Scotney J, et al. Narcolepsy: comorbidities, complexities and future directions. Sleep Med Rev. 2022 Oct;65:101669. Epub 2022 Aug 11. PMID: 36037569. doi: 10.1016/j.smrv.2022.101669
   PubMed Web of Science ®Google Scholar
• Cohen A, Mandrekar J, St Louis EK, et al. Comorbidities in a community sample of narcolepsy. Sleep Med. 2018 Mar;43:14–18. Epub 2017 Nov 21. PMID: 29482805; PMCID: PMC5931205. doi: 10.1016/j.sleep.2017.11.1125
   PubMed Web of Science ®Google Scholar
• Carls G, Reddy SR, Broder MS, et al. Burden of disease in pediatric narcolepsy: a claims-based analysis of health care utilization, costs, and comorbidities. Sleep Med. 2020 Feb;66:110–118. Epub 2019 Aug 26. PMID: 31841742. doi: 10.1016/j.sleep.2019.08.008
   PubMed Web of Science ®Google Scholar
• Jennum PJ, Plazzi G, Silvani A, et al. Cardiovascular disorders in narcolepsy: review of associations and determinants. Sleep Med Rev. 2021 Aug;58:101440. Epub 2021 Jan 23. PMID: 33582582. doi: 10.1016/j.smrv.2021.101440
   PubMed Web of Science ®Google Scholar
• Dodel R, Peter H, Walbert T, et al. The socioeconomic impact of narcolepsy. Sleep. 2004 Sep 15;27(6):1123–1128. PMID: 15532206. doi: 10.1093/sleep/27.6.1123
   PubMed Web of Science ®Google Scholar
• Jennum P, Knudsen S, Kjellberg J. The economic consequences of narcolepsy. J Clin Sleep Med. 2009 Jun 15;5(3):240–245. PMID: 19960645; PMCID: PMC2699169. doi: 10.5664/jcsm.27493
   PubMed Web of Science ®Google Scholar
• Jennum P, Ibsen R, Petersen ER, et al. Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners. Sleep Med. 2012 Sep;13(8):1086–1093. Erratum in: Sleep Med. 2013 Oct;14(10):1039-40. PMID: 22841027. doi: 10.1016/j.sleep.2012.06.006
   PubMed Web of Science ®Google Scholar
• Philip P, Sagaspe P, Lagarde E, et al. Sleep disorders and accidental risk in a large group of regular registered highway drivers. Sleep Med. 2010 Dec;11(10):973–979. Epub 2010 Oct 18. PMID: 20961809. doi: 10.1016/j.sleep.2010.07.010
   PubMed Web of Science ®Google Scholar
• Pizza F, Jaussent I, Lopez R, et al. Car crashes and central disorders of hypersomnolence: a French study. PLoS One. 2015 Jun 8;10(6): e0129386. PMID: 26052938; PMCID: PMC4460078. 10.1371/journal.pone.0129386.
   PubMed Web of Science ®Google Scholar
• Ingravallo F, Gnucci V, Pizza F, et al. The burden of narcolepsy with cataplexy: how disease history and clinical features influence socio-economic outcomes. Sleep Med. 2012 Dec;13(10):1293–1300. Epub 2012 Sep 28. PMID: 23026503. doi: 10.1016/j.sleep.2012.08.002
   PubMed Web of Science ®Google Scholar
• Leprotti S, Audetto E, Zenesini C, et al. What, when and by whom? adolescents’ and parents’ preferences concerning narcolepsy information. Sleep Med. 2023 Jan;101:478–484. Epub 2022 Nov 30. PMID: 36525847. doi: 10.1016/j.sleep.2022.11.030
   PubMed Web of Science ®Google Scholar
• Morgenthaler TI, Kapur VK, Brown T, et al. Standards of practice committee of the American Academy of sleep Medicine. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007 Dec;30(12):1705–1711. Erratum in: Sleep. 2008 Feb 1;31(2):table of contents. PMID: 18246980; PMCID: PMC2276123. doi: 10.1093/sleep/30.12.1705
   PubMed Web of Science ®Google Scholar
• Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881–1893. doi: 10.5664/jcsm.9328.
   PubMed Web of Science ®Google Scholar
• Scammell TE Treatment of narcolepsy in adults. In UptoDate. [cited 2023 Jun 13]. Available from: https://www-uptodate-com.laneproxy.stanford.edu/contents/treatment-of-narcolepsy-in-adults?source=mostViewed_widget.
   Google Scholar
• Franceschini C, Pizza F, Cavalli F, et al. A practical guide to the pharmacological and behavioral therapy of narcolepsy. Neurotherapeutics. 2021 Jan;18(1):6–19. Epub 2021 Apr 22. PMID: 33886090; PMCID: PMC8061157. doi: 10.1007/s13311-021-01051-4
   PubMed Web of Science ®Google Scholar
• Barateau L, Dauvilliers Y. Recent advances in treatment for narcolepsy. Ther Adv Neurol Disord. 2019 Sep 26;12:1756286419875622. PMID: 31632459; PMCID: PMC6767718. doi: 10.1177/1756286419875622
   Web of Science ®Google Scholar
• Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med. 2020Apr; 68:97–109. Epub 2019 Sep 11. PMID: 32032921. doi: 10.1016/j.sleep.2019.09.001.
   PubMed Web of Science ®Google Scholar
• Abad VC. Calcium, magnesium, potassium, and sodium oxybates oral solution for cataplexy or excessive daytime sleepiness associated with narcolepsy. Expert Opin Pharmacother. 2023 Jun;24(8):875–885. Epub 2023 Apr 20. PMID: 37060579. doi: 10.1080/14656566.2023.2204187
   PubMed Web of Science ®Google Scholar
• Pellitteri G, de Biase S, Valente M, et al. How treatable is narcolepsy with current pharmacotherapy and what does the future hold? Expert Opin Pharmacother. 2021 Aug;22(12):1517–1520. Epub 2021 Apr 22. PMID: 33882765. doi: 10.1080/14656566.2021.1915987
   PubMed Web of Science ®Google Scholar
• Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021 Sep 1;17(9):1895–1945. PMID: 34743790; PMCID: PMC8636345. doi: 10.5664/jcsm.9326.
   PubMed Web of Science ®Google Scholar
• Sodium Oxybate Drug Summary. In Pdr.Net. [cited 2023 Jun 19]. Ava: https://www.pdr.net/drug-summary/Xyrem-sodium-oxybate-281.3903.
   Google Scholar
• Abad VC. An evaluation of sodium oxybate as a treatment option for narcolepsy. Expert Opin Pharmacother. 2019 Jul;20(10):1189–1199. Epub 2019 May 28. PMID: 31136215. doi: 10.1080/14656566.2019.1617273
   PubMed Web of Science ®Google Scholar
• Pitolisant drug summary. In Wakix.Com [cited 2023 Jun 19]. Available fom: https://wakix.com/?gclid=EAIaIQobChMInIiqzY_Q_wIV-BitBh221w9kEAAYASAAEgKZTPD_BwE.
   Google Scholar
• de Biase S, Pellitteri G, Gigli GL, et al. Evaluating pitolisant as a narcolepsy treatment option. Expert Opin Pharmacother. 2021 Feb;22(2):155–162. Epub 2020 Sep 17. PMID: 32941089. doi: 10.1080/14656566.2020.1817387
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Bassetti C, Lammers GJ, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12:1068e75. doi: 10.1016/S1474-4422(13)70225-4
   Web of Science ®Google Scholar
• Szakacs Z, Dauvilliers Y, Mikhaylov V, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:200e7. doi: 10.1016/S1474-4422(16)30333-7
   Web of Science ®Google Scholar
• Venlafaxine. In Pdr.Net.[cited 2023 Jun 19]. Available from: https://www.pdr.net/drug-summary/Venlafaxine-Tablets-venlafaxine-hydrochloride-1361.3059.
   Google Scholar
• Fluoxetine. In Pdr.Net. [cited 2023 Jun 19]. Available fom: https://www.pdr.net/drug-summary/Fluoxetine-Hydrochloride-fluoxetine-hydrochloride-24302
   Google Scholar
• Clomipramine. In Pdr.Net. [cited 2023 Jun 19]. Ava: https://www.pdr.net/drug-summary/Anafranil-clomipramine-hydrochloride-678.
   Google Scholar
• Modafinil Drug Summary. In pdr.net. [cited 2023 Jun 19]. Available fom: https://www.pdr.net/drug-summary/Provigil-modafinil-2332.
   Google Scholar
• Armodafinil Drug Summary. In pdr.net. [cited 2023 Jun 19]. Available fom: https://www.pdr.net/drug-summary/Nuvigil-armodafinil-2335.
   Google Scholar
• Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US modafinil in narcolepsy multicenter study group. Ann Neurol. 1998 Jan;43(1):88–97. PMID: 9450772. doi: 10.1002/ana.410430115
   PubMed Web of Science ®Google Scholar
• Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US modafinil in narcolepsy multicenter study group. Neurology. 2000 Mar 14;54(5): 1166–1175. PMID: 10720292. doi: 10.1212/wnl.54.5.1166
   PubMed Web of Science ®Google Scholar
• Solriamfetol Drug Summary pdr.net. [cited 2023 Jun 19]. Available fom: https://www.pdr.net/drug-summary/Sunosi-solriamfetol-24354.
   Google Scholar
• Abad VC. Profile of solriamfetol in the management of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea: focus on patient selection and perspectives. Nat Sci Sleep. 2021 Jan 25;13: 75–91. PMID: 33531850; PMCID: PMC7846869. doi: 10.2147/NSS.S245020
   PubMed Web of Science ®Google Scholar
• Ruoff C, Swick TJ, Doekel R, et al. Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study. Sleep. 2016;39(7):1379–1387. doi: 10.5665/sleep.5968
   PubMed Web of Science ®Google Scholar
• Thorpy MJ, Shapiro C, Mayer G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy [published correction appears in Ann Neurol. Ann Neurol. 2020 Jan;87(1):157]. doi: 10.1002/ana.25423.
   Web of Science ®Google Scholar
• Methylphenidate Drug Summary pdr.net. [cited 2023 Jun 19]. Available fom: https://www.pdr.net/drug-information/concerta?druglabelid=267.
   Google Scholar
• Dextroamphetamine Drug Summary pdr.net. [cited 2023 Jun 19]. Ava: https://www.pdr.net/drug-information/dexedrine?druglabelid=2211.
   Google Scholar
• Amphetamine-dextroamphetamine drug summary. pdr.net. [cited 2023 Jun 19]. Ava: https://www.pdr.net/drug-summary/Adderall-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-saccharate-dextroamphetamine-sulfate-1048.
   Google Scholar
• Mayer G, Ewert Meier K, Hephata K. Selegiline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol. 1995 Aug;18(4):306–319. PMID: 8665543. Old # 155. doi: 10.1097/00002826-199508000-00002
   PubMed Web of Science ®Google Scholar
• Sodium oxybate XR drug summary. In pdr.net. [cited 2023 Jun 19]. Available fom: https://www.pdr.net/drug-summary/LUMRYZ-sodium-oxybate-24474.
   Google Scholar
• Thakrar C, Patel K, D’ancona G, et al. Effectiveness and side-effect profile of stimulant therapy as monotherapy and in combination in the central hypersomnias in clinical practice. J Sleep Res. 2018 Aug;27(4):e12627. Epub 2017 Oct 19. PMID: 29047171; PMCID: PMC6558259. doi: 10.1111/jsr.12627
   PubMed Web of Science ®Google Scholar
• Almeneessier AS, Alballa NS, Alsalman BH, et al. A 10-year longitudinal observational study of cataplexy in a cohort of narcolepsy type 1 patients. Nat Sci Sleep. 2019 Oct;21;11:231–239. Erratum in: Nat Sci Sleep. 2020 Aug 26;12:635. PMID: 31695532; PMCID: PMC6814360. doi: 10.2147/NSS.S229105
   Web of Science ®Google Scholar
• Lehert P, Falissard B. Multiple treatment comparison in narcolepsy: a network meta-analysis. Sleep. 2018 Dec 1;41(12):zsy185. PMID: 30239930; PMCID: PMC6289237. doi: 10.1093/sleep/zsy185
   PubMed Web of Science ®Google Scholar
• Zhan S, Ye H, Li N, et al. Comparative efficacy and safety of multiple wake-promoting agents for the treatment of excessive daytime sleepiness in narcolepsy: a network meta-analysis. Nat Sci Sleep. 2023 Apr 14;15:217–230. PMID: 37082610; PMCID: PMC10112483. doi: 10.2147/NSS.S404113
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Carlander B, Rivier F, et al. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol. 2004 Dec;56(6):905–908. doi: 10.1002/ana.20339
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Abril B, Mas E, et al. Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology. 2009 Oct 20;73(16):1333–1334. doi: 10.1212/WNL.0b013e3181bd1344
   PubMed Web of Science ®Google Scholar
• Plazzi G, Poli F, Franceschini C, et al. Intravenous high-dose immuno-globulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol. 2008;255(10):1549–1554. doi: 10.1007/s00415-008-0983-7
   PubMed Web of Science ®Google Scholar
• Ruppert E, Zagala H, Chambe J, et al. Intravenous immunoglobulin therapy administered early after narcolepsy type 1 onset in three patients evaluated by clinical and polysomnographic follow-up. Behav Neurol. 2018 Oct 15;2018:1671072. PMID: 30410634; PMCID: PMC6205306. doi: 10.1155/2018/1671072
   PubMed Web of Science ®Google Scholar
• Chen W, Black J, Call P, et al. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann Neurol. 2005;58(3):489–490. doi: 10.1002/ana.20603
   PubMed Web of Science ®Google Scholar
• Hecht M, Lin L, Kushida CA, et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep. 2003;26(7):809–810. doi: 10.1093/sleep/26.7.809
   PubMed Web of Science ®Google Scholar
• Coelho FM, Pradella-Hallinan M, Alves GR, et al. Report of two narcoleptic patients with remission of hypersomnolence following use of prednisone. Arq Neuropsiquiatr. 2007 Jun;65(2A):336–337. doi: 10.1590/S0004-282X2007000200028
   PubMed Web of Science ®Google Scholar
• Sarkanen T, Alén R, Partinen M. Transient impact of rituximab in H1N1 vaccination-associated narcolepsy with severe psychiatric symptoms. Neurologist. 2016 Sep;21(5):85–86. PMID: 27564078. doi: 10.1097/NRL.0000000000000099
   PubMed Web of Science ®Google Scholar
• Wasling P, Malmeström C, Blennow K. CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1. Neurol(r) Neuroimmunol Neuroinflammation. 2019 Sep 4;6(6):e613. PMID: 31484686; PMCID: PMC6745716. doi: 10.1212/NXI.0000000000000613
   PubMed Web of Science ®Google Scholar
• Donjacour CEHM, Lammers GJ. A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy. J Sleep Res. 2012;21(4):479–480. doi: 10.1111/j.1365-2869.2011.00985.x
   PubMed Web of Science ®Google Scholar
• Giannoccaro MP, Liguori R, Plazzi G, et al. Reviewing the clinical implications of treating narcolepsy as an autoimmune disorder. Nat Sci Sleep. 2021 May 11;13:557–577. PMID: 34007229; PMCID: PMC8123964. doi: 10.2147/NSS.S275931
   PubMed Web of Science ®Google Scholar
• Arias-Carrion O, Murillo-Rodriguez E, Xu M, et al. Transplant of hypocretin neurons into the pontine reticular formation: preliminary results. Sleep. 2004;27:1465–1470. doi: 10.1093/sleep/27.8.1465
   PubMed Web of Science ®Google Scholar
• Arias-Carrión O, Murillo-Rodríguez E. Cell transplantation: a future therapy for narcolepsy? CNS Neurol Disord Drug Targets. 2009 Aug;8(4):309–314. PMID: 19689312. doi: 10.2174/187152709788921681
   PubMed Web of Science ®Google Scholar
• Arias-Carrion O, Murillo-Rodriguez E, Androutsellis-Theotokis A. Effects of hypocretin/orexin cell transplantation on narcoleptic-like sleep behavior in rats. PLoS One. 2014 Apr 15;9(4):e95342. eCollection 2014. doi: 10.1371/journal.pone.0095342
   PubMed Web of Science ®Google Scholar
• Hayakawa K, Hirosawa M, Tabei Y, et al. Epigenetic switching by the metabolism-sensing factors in the generation of orexin neurons from mouse embryonic stem cells. J Biol Chem. 2013 Jun 14;288(24):17099–17110. Epu. doi: 10.1074/jbc.M113.455899
   PubMed Web of Science ®Google Scholar
• Wang L, Meece K, Williams DJ, et al. Differentiation of hypothalamic-like neurons from human pluripotent stem cells. J Clin Invest. 2015 Feb 2Epub 2015 Jan 2;125(2):796–808. doi: 10.1172/JCI79220
   PubMed Web of Science ®Google Scholar
• Merkle FT, Maroof A, Wataya T, et al. Generation of neuropeptidergic hypothalamic neurons from human pluripotent stem cells. Development. 2015 Feb 15;142(4):633–643. PMID: 25670790; PMCID: PMC4325380. doi: 10.1242/dev.117978
   PubMed Web of Science ®Google Scholar
• Mieda M, Willie JT, Hara J, et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A. 2004;101(13):4649–4654. doi: 10.1073/pnas.0400590101
   PubMed Web of Science ®Google Scholar
• Liu M, Thankachan S, Kaur S, et al. Orexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in mice. Eur J Neurosci. 2008 Oct;28(7):1382–1393. doi: 10.1111/j.1460-9568.2008.06446.x
   PubMed Web of Science ®Google Scholar
• Liu M, Blanco-Centurion C, Konadhode R, et al. Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice. J Neurosci. 2011 Apr 20;31(16):6028–6040. doi: 10.1523/JNEUROSCI.6069-10.2011
   PubMed Web of Science ®Google Scholar
• Blanco-Centurion C, Liu M, Konadhode R, et al. Effects of orexin gene transfer in the dorsolateral pons in orexin knockout mice. Sleep. 2013 Jan 1;36(1):31–40. doi: 10.5665/sleep.2296
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH. Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J Pharm Sci. 2009 Jul 2nd;98(7):2501–2515.
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH. Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system. J Pharmacol Exp Ther. 2009 Jan 2nd;328(1):312–320. Epub 2008 Oct 22. PMID: 18945930. doi: 10.1124/jpet.108.145565
   PubMed Web of Science ®Google Scholar
• Baier PC, Hallschmid M, Seeck-Hirschner M. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med. 2011;12(10):941–946. doi: 10.1016/j.sleep.2011.06.015
   PubMed Web of Science ®Google Scholar
• Weinhold SL, Seeck-Hirschner M, Nowak A, et al. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res. 2014 Apr 1;262:8–13. Epub 14 Jan 7. doi: 10.1016/j.bbr.2013.12.045
   PubMed Web of Science ®Google Scholar
• Nagahara T, Saitoh T, Kutsumura N, et al. Design and synthesis of non-peptide, selective orexin receptor 2 agonists. J Med Chem. 2015 Oct 22;58(20):7931–7937. Epu. doi: 10.1021/acs.jmedchem.5b00988
   PubMed Web of Science ®Google Scholar
• Irukayama-Tomobe Y, Ogawa Y, Tominaga H, et al. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. Proc Natl Acad Sci U S A. 2017 May 30;114(22): 5731–5736. Epub 2017 May 15. PMID: 28507129; PMCID: PMC5465922. 10.1073/pnas.1700499114.
   PubMed Web of Science ®Google Scholar
• Niewoehner J, Bohrmann B, Collin L, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014 Jan 8;81(1):49–60. doi: 10.1016/j.neuron.2013.10.061
   PubMed Web of Science ®Google Scholar
• Takenoshita S, Sakai N, Chiba Y, et al. An overview of hypocretin based therapy in narcolepsy. Expert Opin Investig Drugs. 2018 Apr;27(4):389–406. Epub 2018 Apr 9. PMID: 29623725. doi: 10.1080/13543784.2018.1459561
   PubMed Web of Science ®Google Scholar
• Fujiki N, Yoshida Y, Ripley B, et al. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin- ligand-deficient narcoleptic dog. Sleep. 2003;26(8):953–959. doi: 10.1093/sleep/26.8.953
   PubMed Web of Science ®Google Scholar
• Justinussen JL, Egebjerg C, Kornum BR. How hypocretin agonists may improve the quality of wake in narcolepsy. Trends Mol Med. 2023 Jan;29(1):61–69. Epub 2022 Nov 16. PMID: 36400667. doi: 10.1016/j.molmed.2022.10.008
   PubMed Web of Science ®Google Scholar
• Yin J, Kang Y, McGrath AP, et al. Molecular mechanism of the wake-promoting agent TAK-925. Nat Commun. 2022;13(1):2902. doi: 10.1038/s41467-022-30601-3
   PubMed Web of Science ®Google Scholar
• Tanaka S-I, Evans R, Alexander R, et al. Selective orexin 2 receptor agonist TAK-925 to treat narcolepsy: results of a randomized, double-blind, placebo-controlled, multiple-ascending-dose, phase 1 study in patients with narcolepsy type 1. J Sleep Res. 2020 [28 Feb 2021];29(SUPPL 1). | added to CENTRAL:| 2021 Issue 02. doi:10.1111/jsr.13181
   Google Scholar
• Takeda update on TAK-994. [cited 2023 Jun 3]. Available from https://www.takeda.com/newsroom/newsreleases/2021/takeda-provides-updateon-tak-994-clinical-program/
   Google Scholar
• Jazz acquires DSP-0187. [cited 2023 Jun 3]. Available from: https://www.neurologylive.com/view/jazz-acquires-narcolepsy-hopeful-dsp-0187-jzp441-agreement-sumitomo-pharma
   Google Scholar
• Inoue Y, Uchiyama M, Umeuchi H, et al. Optimal dose determination of enerisant (TS-091) for patients with narcolepsy: two randomized, double-blind, placebo-controlled trials. BMC Psychiatry. 2022 Feb 22;22(1):141. doi: 10.1186/s12888-022-03785-7
   PubMedGoogle Scholar
• Nirogi R, Ravula J, Jayarajan P, et al. Samelisant, histamine 3 receptor agonist for the potential treatment of excessive daytime sleepiness in patients with narcolepsy. Sleep. 2023;46(Supp 1):A267. doi: 10.1093/sleep/zsad077.0609
   Google Scholar
• A safety and effectiveness study of a single dose of JNJ-17216498 in patients with narcolepsy. [cited 2022 Dec 24]. Available from https://clinicaltrials.gov/ct2/show/NCT00424931?term=JNJ+17216498&cond=narcolepsy&draw=2&rank=1
   Google Scholar
• Larrosa O, de la Llave Y, Bario S, et al. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep. 2001 May 1;24(3):282–285. PMID: 11322710. doi: 10.1093/sleep/24.3.282
   PubMed Web of Science ®Google Scholar
• O’Gorman C, Jones A, Thorpy MJ. 0739 efficacy and safety of AXS-12 in the treatment of narcolepsy: results from a phase 2, double-blind, placebo-controlled, crossover trial. Sleep. 2020 Apr;43(Supplement_1):A281. doi: 10.1093/sleep/zsaa056.735
   Google Scholar
• Szabo ST, Hopkins SC, Lew R, et al. A multicenter, double-blind, placebo-controlled, randomized, phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy. Sleep Med. 2023 Jul;107:202–211. Epub 2023 Apr 28. PMID: 37209427. doi: 10.1016/j.sleep.2023.04.019
   PubMed Web of Science ®Google Scholar
• Corser B, Stern T, Bogan R, et al. A four-week randomized, double-blind, placebo-controlled, phase 2 study of Mazindol ER in the treatment of narcolepsy. Abs Sleep. 2023;46(Supplement1):A257. doi: 10.1093/sleep/zsad077.0585
   Google Scholar
• Bogan R, Stern T, Corser B, et al. Clinician and patient Global Impression in a phase 2 study of Mazindol (NLS-1021) in adults with narcolepsy type 1 and type 2. Abs Sleep. 2023;46(Supplement 1):A254. doi: 10.1093/sleep/zsad077.0578
   Google Scholar
• Theranos announces preliminary results of phase 11 trial of THN102 on narcolepsy patients [Press Release]. [cited 2022 Dec 11]. Available from: https://www.theranexus.com/images/pdf/TheranexusPRresultnarcolepsy20199227VDEF.pdf
   Google Scholar
• Trotti LM, Saini P, Bliwise DL, et al. Clarithromycin in γ-aminobutyric acid-related hypersomnolence: a randomized, crossover trial. Ann Neurol. 2015 Sep;78(3):454–465. doi: 10.1002/ana.24459
   PubMed Web of Science ®Google Scholar
• Lammers GJ, Bassetti CLA, Dauvilliers Y, et al. Commentary on diagnosis of central disorders of hypersomnolence: challenges in defining central disorders of hypersomnolence. Sleep Med Rev. 2020 Aug;52:101326. Epub 2020 Apr 26. PMID: 32408090. doi: 10.1016/j.smrv.2020.101326
   PubMed Web of Science ®Google Scholar
• Lammers GJ, Bassetti CLA, Dauvilliers Y, et al. Commentary on diagnosis of central disorders of hypersomnolence: from clinic to clinic via ontology and semantic analysis on a bullet point path. Sleep Med Rev. 2020 Aug;52:101329. Epub 2020 Apr 26. PMID: 32408089. doi: 10.1016/j.smrv.2020.101329
   PubMed Web of Science ®Google Scholar
• Cesari M, Egger K, Stefani A, et al. A. Differentiation of central disorders of hypersomnolence with manual and artificial-intelligence-derived polysomnographic measures. Sleep. 2023 Feb 8;46(2):zsac288. PMID: 36455881. doi: 10.1093/sleep/zsac288
   PubMed Web of Science ®Google Scholar
• Son DY, Kwon HB, Lee DS, et al. Changes in physiological network connectivity of body system in narcolepsy during REM sleep. Comput Biol Med. 2021 Sep;136:104762. Epub 2021 Aug 10. PMID: 34399195. doi: 10.1016/j.compbiomed.2021.104762
   PubMed Web of Science ®Google Scholar
• Exarchos I, Rogers AA, Aiani LM, et al. Supervised and unsupervised machine learning for automated scoring of sleep-wake and cataplexy in a mouse model of narcolepsy. Sleep. 2020 May 12;43(5): zsz272. PMID: 31693157; PMCID: PMC7215268. 10.1093/sleep/zsz272.
   PubMed Web of Science ®Google Scholar
• Sanni A, Goli M, Zhao J, et al. LC-MS/MS-Based proteomics approach for the identification of candidate serum biomarkers in patients with narcolepsy type 1. Biomolecules. 2023 Feb 23;13(3):420. PMID: 36979356; PMCID: PMC10046664. doi: 10.3390/biom13030420
   PubMed Web of Science ®Google Scholar
• Lanza G, Fisicaro F, Cantone M, et al. Repetitive transcranial magnetic stimulation in primary sleep disorders. Sleep Med Rev. 2023 Feb;67:101735. Epub 2022 Dec 8. PMID: 36563570. doi: 10.1016/j.smrv.2022.101735
   PubMed Web of Science ®Google Scholar
• Civardi C. Transcranial magnetic stimulation in sleep disorders: a reappraisal. Sleep Med. 2013 Nov;14(11):1043–1044. Epub 2013 Aug 29. PMID: 23993874. doi: 10.1016/j.sleep.2013.07.004
   PubMed Web of Science ®Google Scholar
• Hungs M, Mottaghy FM, Sparing R, et al. RTMS induces brief events of muscle atonia in patients with narcolepsy. Sleep. 2000 Dec 15;23(8): 1099–1104. PMID: 11145324. 10.1093/sleep/23.8.1i.
   PubMed Web of Science ®Google Scholar
• Overeem S, Afink J, Bakker M, et al. High frequency repetitive transcranial magnetic stimulation over the motor cortex: no diagnostic value for narcolepsy/cataplexy. J Neurol. 2007 Oct;254(10):1459–1461. Epub 2007 Jun 25. PMID: 17579803; PMCID: PMC2778683. doi: 10.1007/s00415-007-0562-3
   PubMed Web of Science ®Google Scholar
• Lai JB, Han MM, Xu Y, et al. Effective treatment of narcolepsy-like symptoms with high-frequency repetitive transcranial magnetic stimulation: a case report. Medicine (Baltimore). 2017 Nov;96(46):e8645. PMID: 29145290; PMCID: PMC5704835. doi: 10.1097/MD.0000000000008645
   PubMed Web of Science ®Google Scholar
• Ouyang H, Zhou Z, Zheng Q, et al. Analyzing functional pathways and constructing gene-gene network for narcolepsy based on candidate genes. Int J Med Sci. 2020 Jun 15;17(11): 1508–1514. PMID: 32669953; PMCID: PMC7359385. 10.7150/ijms.41812.
   PubMed Web of Science ®Google Scholar
• Ortiz L, Morse A, Krahn L, et al. Understanding narcolepsy treatments from the patient’s perspective: a survey of people living with narcolepsy. Abs Sleep. 2023;46(Supp 1):A268. doi: 10.1093/sleep/zsad077.0612
   Google Scholar
• Dietmann A, Wenz E, van der Meer J, et al. The Swiss primary hypersomnolence and narcolepsy cohort study (SPHYNCS): study protocol for a prospective, multicentre cohort observational study. J Sleep Res. 2021 Oct;30(5):e13296. Epub 2021 Apr 4. PMID: 33813771; PMCID: PMC8519114. doi: 10.1111/jsr.13296
   PubMed Web of Science ®Google Scholar
• Tashima T Smart strategies for therapeutic agent delivery into brain across the blood-brain barrier using receptor-mediated transcytosis. Chem Pharm Bull (Tokyo). 2020;68(4):316–325. PMID: 32238649. doi: 10.1248/cpb.c19-00854
   PubMed Web of Science ®Google Scholar
• Choi H, Choi K, Kim DH, et al. Strategies for targeted delivery of exosomes to the brain: advantages and Challenges. Pharmaceutics. 2022 Mar 18;14(3):672. PMID: 35336049; PMCID: PMC8948948. doi: 10.3390/pharmaceutics14030672
   PubMed Web of Science ®Google Scholar
• Tafti M, Dauvilliers Y. Pharmacogenomics in the treatment of narcolepsy. Pharmacogenomics. 2003 Jan;4(1):23–33. PMID: 12517283. doi: 10.1517/phgs.4.1.23.22590
   PubMed Web of Science ®Google Scholar
• Moresco M, Riccardi LN, Pizza F, et al. Pharmacogenetics and treatment response in narcolepsy type 1: relevance of the polymorphisms of the drug transporter gene ABCB1. Clin Neuropharmacol. 2016 Jan;39(1):18–23. PMID: 26757307. doi: 10.1097/WNF.0000000000000119
   PubMed Web of Science ®Google Scholar
• Kam H, Jeong H. Pharmacogenomic biomarkers and their applications in Psychiatry. Genes (Basel). 2020 Nov 30;11(12):1445. PMID: 33266292; PMCID: PMC7760818. doi: 10.3390/genes11121445
   PubMed Web of Science ®Google Scholar
• Ben-Joseph RH, Saad R, Black J, et al. Cardiovascular burden of narcolepsy disease (CV-BOND): a real-world evidence study. Sleep. 2023 Jun 12:p. zsad161. doi: 10.1093/sleep/zsad161. Epub ahead of print. PMID: 37305967.
   Google Scholar